International Physician Networks dba International Urology Network and Theragenics Corporation Sign Exclusive Three-Year Strateg
November 10 2004 - 10:12AM
PR Newswire (US)
International Physician Networks dba International Urology Network
and Theragenics Corporation Sign Exclusive Three-Year Strategic
Alliance BALTIMORE, Nov. 10 /PRNewswire-FirstCall/ -- International
Physician Networks dba International Urology Network (IUN)
announced today that it has entered into a three-year exclusive,
strategic, alliance agreement with Theragenics Corporation(R)
(NYSE:TGX). This agreement will provide group purchasing services
to over 3,500 of IUN's community-based urologists for Theragenics
Corporation(R)'s palladium-103 device TheraSeed(R) and I-Seed, an
iodine-125-based device. It also has the potential to expand the
strategic relationship to include medical education programming to
IUN's growing urology physician practice membership. "We are
pleased to have the opportunity to work with Theragenics
Corporation(R), a leading provider of brachytherapy treatment
devices for prostate cancer. We look forward to helping them
improve the health and quality of life for prostate cancer
patients," said Anthony J. Corrao, Executive Vice President, Global
Sales and Development of International Physician Networks. "Our
community-based urology practices have expressed their interest in
expanding their ancillary services and have specifically targeted
brachytherapy as a preferred treatment option." "This new
relationship with IUN presents several opportunities for
Theragenics. IUN brings groups of physicians, specifically
urologists in their position as gatekeepers, into an arena that
could benefit brachytherapy as a whole," said Christine M. Jacobs,
Chairman, CEO and President of Theragenics Corporation(R). "It is
our hope this relationship provides a fresh channel for exposure of
prostate cancer patients to brachytherapy. It also holds promise
for those loyal radiation oncologists who recognize our treatment
option for prostate cancer is the new gold standard. IUN is one of
the first groups of its kind to identify this unique opportunity
and we look forward to being a part of their success in this
exciting endeavor." Theragenics Corporation(R) is committed to
being a leading provider of brachytherapy treatment devices for
prostate cancer and other degenerative disease states. The company
is the manufacturer and marketer of the palladium-103 device
TheraSeed(R) and I-Seed, an iodine-125-based device. Both devices
are used in the treatment of localized prostate cancer in one-time,
minimally invasive procedures. Theragenics(R) is the world's
largest producer of palladium-103 and is involved in research and
development utilizing palladium-103 and other isotopes for the
treatment of a wide variety of diseases, including vascular disease
and macular degeneration. For additional information on the
company, call Theragenics' Investor Relations Department at (800)
998-8479. Additional information can be found on the company
website: http://www.theragenics.com/. International Physician
Networks is a subsidiary of AmerisourceBergen Corporation
(NYSE:ABC), the world's leading pharmaceutical distributor. IPN is
a diversified physician services organization specializing in the
support of community-based practices. The company offers its
members a variety of value-added services that enable practices to
remain efficient, effective, and to continue to deliver quality
patient care. DATASOURCE: International Physician Networks CONTACT:
Erin Mulgrew of International Physician Networks, +1-410-385-2900
or Web site: http://www.theragenics.com/ Web site:
http://www.ipnonline.com/
Copyright
Theragenics (NYSE:TGX)
Historical Stock Chart
From Apr 2024 to May 2024
Theragenics (NYSE:TGX)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Theragenics Corp. (New York Stock Exchange): 0 recent articles
More Theragenics Corp News Articles